Millennium Pharmaceuticals Limited

Biogen Ma Inc.

Biogen Idec Ma Inc.

Zhan Shi

Paul E Fleming

Geraldine C B Harriman

Stepan Vyskocil

Arthur G Taveras

Gnanasambandam Kumaravel

Kevin Guckian

Geraldine C Harriman

Bin Ma

Guo Zhu Zheng

Richard Dana Caldwell

Daniel M Scott

Wen-Cherng Lee

Edward Yin-Shiang Lin

Jermaine Thomas

Xiaogao Liu

Masaaki Hirose

Hong Myung Lee

Yongbo Hu

Tianlin Xu

B Shaowu Chen

Brian Scott Freeze

Todd B Sells

John Charles Reader

Kenneth M Gigstad

Jeffrey P Ciavarri

Jane F Schmidt

Zhigen Hu

Brendan Chen

Neal D Hone

Shaowu Chen

Chen Shaowu

Tricia J Vos

Francois Soucy

Irache B Visiers

Takaharu Hirayama

Noriyuki Nii

Hiroyuki Watanabe

David P Cardin

Takashi Motoyaji

Hiroyuki Kakei

David A Janowick

Leo R Takaoka

Kevin M Guckian

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R, R, o, R, W and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease. 

Quinazoline and quinoline compounds and uses thereof

This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R, R, o, R, and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease. 

Quinoxaline compounds and uses thereof

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Heterobicyclic sphingosine 1-phosphate analogs

This invention provides compounds of formula IA or IB: wherein HY, R, R, G, W, n, and A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders. 

Heteroaryls and uses thereof

The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

CCR9 inhibitors and methods of use thereof

This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

This invention provides compounds of formula IA-a or IB-a and subsets thereof: wherein Z, HY, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

This invention provides compounds of formula I: 

This invention provides compounds of formula I-A or I-B: wherein HY, G, G, R, R, W, W, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors.

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds of formula (I): that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role: 

2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases

Growing community of inventors

Concord, MA, United States of America

Zhan Shi